Daewon Pharmaceutical Launches New Dyslipidemia Treatment 'Uptava Extended-Release Tablets'
"Ensures Both Safety and Convenience of Administration"
Daewon Pharmaceutical announced on June 15 that it has launched a new combination therapy for dyslipidemia, Uptava Extended-Release Tablets.
Uptava Extended-Release Tablets are a combination therapy for dyslipidemia, containing 2 mg of pitavastatin calcium and 178.8 mg of fenofibrate choline as the main ingredients. The new product has improved medication convenience and treatment persistence by converting the existing capsule formulation into an extended-release tablet form.
Daewon Pharmaceutical's new dyslipidemia treatment product, 'Uptava Extended-Release Tablets'. Daewon Pharmaceutical
View original imageFor Uptava Extended-Release Tablets, the main ingredient has been changed from the conventional granule form to fenofibrate choline, ensuring equivalent efficacy regardless of food intake. To enhance convenience, the tablet size has also been reduced to be the smallest among combination products with the same active ingredients currently available on the market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Daewon Pharmaceutical representative stated, “Uptava Extended-Release Tablets combine pitavastatin, which reduces the risk of adverse reactions associated with statin monotherapy, with fenofibrate, which is highly effective in controlling triglycerides. With the convenience of administration regardless of food intake and the significantly smaller tablet size, this product will provide a more useful treatment option for patients with combination-type dyslipidemia.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.